We use small files called cookies to help us improve your experience on this website and to provide services like web chat. We also use cookies to measure the effectiveness of public health campaigns and understand how people use the website.

Read our cookies policy to find out more about cookies and how we use them.

PCSK9 Inhibitors

Repatha (evolocumab) 140 mg solution for injection in Sureclick pre-filled pen is available under the High Tech Arrangement from 1 July 2019. A Managed Access Protocol is in place for Repatha. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of Repatha under the High Tech Arrangement.

The prescribing of Repatha under the High Tech Arrangement will initially be confined to designated clinicians who have agreed to the terms of the HSE-Managed Access Protocol and have been approved by the HSE-Medicines Management Programme. The clinician must submit an application for individual reimbursement approval for each patient. Applications for individual reimbursement approval will only be considered from approved clinicians.

A copy of the HSE-Managed Access Protocol for Repatha and the application form for individual reimbursement approval can be found in the Related Files section below. 

Clinical Strategy and Programmes Division